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P R E V I E WABCG1: How critical
for cholesterol transport?
In the current issue of Cell Metabolism, Kennedy et al. (2005) have extended our understanding of the ABCG1 transporter.
Their studies demonstrate that, at least in macrophages, ABCG1 is responsible for much of the cholesterol efflux that
utilizes mature HDL as an acceptor.cThe amount of cholesterol that is carried
ein the plasma in the form of high-density
dlipoproteins (HDL-C) is an important pre-
sdictor of atherosclerotic disease. Al-
2though there are some nuances, overall
eit is abundantly clear that the higher the
eHDL-C, the lower the risk. Less clear
chas been the reason for this association.
dMany mechanisms have been proposed,
tbut the facilitation of so-called “reverse
Hcholesterol transport” to the liver, in par-
(ticular from macrophage foam cells in
patheromas, has emerged as the domi-
pnant hypothesis (Ascaso et al., 2004).
lMembers of the ATP binding cassette
t(ABC) transmembrane transporter family
thave come under scrutiny as possibly
mplaying an important role in this process.
bIn this issue of Cell Metabolism, Ken-
rnedy et al. explore the role of ABCG1 in
icholesterol transport, using both gene
oknockout and transgenic techniques in
lmice, along with in vitro studies. The re-
Psults are surprising and should prompt
cthe reservation of judgment regarding
the metabolic significance of reverse p
cholesterol transport to mature HDL. a
sABC transporters came to the atten-
tion of HDL biologists through the dis- s
Hcovery of the role of ABCA1. An extreme
form of hereditary low HDL-C, Tangier L
Disease, was found to stem from the ab-
sence of the ABCA1 gene product (Bod- l
szioch et al., 1999; Brooks-Wilson et al.
1999; Lawn et al., 1999; Rust et al., b
m1999), a protein important for the forma-
tion of HDL, through its initial lipidation g
kof apolipoproteins (Rye and Barter,
2004). However, ABCA1 does not signif- f
nicantly mediate cholesterol efflux to ma-
ture HDL (Wang et al., 2000), and heredi- u
ztary variation in the ABCA1 gene appears
to have (modest) significance in deter- s
cmining HDL levels, only in individuals
with the very lowest levels (Frikke- T
aSchmidt et al. 2004).
Another ABC transporter, ABCG1, was e
tsubsequently suggested to be involved inCELL METABOLISM : FEBRUARY 2005holesterol efflux to mature HDL (Klucken g
t al., 2000). A large body of in vitro evi- p
ence was subsequently marshaled in i
upport of such a view (Wang et al., n
004). By utilizing both ABCG1 over- c
xpression and the “knockdown” of t
xpression via small interfering RNA in p
ultured macrophages, Wang et al. s
emonstrated that ABCG1 can mediate d
he mass efflux of cellular cholesterol to l
DL but not to lipid-poor apolipoprotein n
apo) A-I (Wang et al., 2004). The authors c
ointed out that “ABCG1 is highly ex-
ressed in macrophages” and specu- (
ated that it “probably mediates choles- w
erol efflux from macrophage foam cells l
o the major HDL fractions, providing a i
echanism to explain the relationship d
etween HDL levels and atherosclerosis p
isk.” Like ABCA1, expression of ABCG1 v
s activated by liver X receptor (LXR) ag- s
nists that promote macrophage cho- a
esterol efflux (Kennedy et al., 2001). c
eroxisomal proliferator activated re- w
eptor-γ (PPAR-γ) activators, which also c
romote macrophage cholesterol efflux c
wnd are anti-atherogenic, have been
hown in vivo to increase ABCG1 expres- n
tion and stimulate cholesterol efflux to
DL, independently of their induction of f
tXR and ABCA1 (Li et al., 2004).
In the current issue of Cell Metabo- H
pism, Kennedy et al. extend our under-
tanding of the ABCG1 transporter. They m
cegin with an in vivo approach, studying
ice carrying a knockout of the Abcg1 d
tene. Heterozygous and homozygous
nockout mice were viable and normally p
pertile. Interestingly, heterozygotes had
ormal levels of ABCG1 mRNA. Quite
knlike ABCA1 knockouts, young homo-
ygotes were grossly normal, as as- t
Hessed by weight, plasma lipids, a blood
hemistry panel, and tissue pathology. w
khe knockout allele was constructed to
llow ABCG1 enhancer/promoter-driven t
sxpression of lacZ, producing a sensi-
ive assay for the level and pattern of eene expression. High levels of lacZ ex-
ression were observed in macrophages
n a wide variety of sites, along with
ovel sites of expression: endothelial
ells and both renal and pulmonary epi-
helial cells. An LXR ligand increased ex-
ression at some, but not all, of these
ites. Expression in the liver was pre-
ominantly in Kupffer cells and endothe-
ial cells but “very low” levels of the
ative mRNA were detected in hepato-
ytes by in situ hybridization.
Even on a very high-cholesterol diet
21% fat and 1.25% cholesterol), there
as no difference in plasma lipoprotein
evels between knockout and control an-
mals. However, knockout mice on this
iet did have grossly visible pleural
laques, and histological analysis re-
ealed markedly increased pleural and
ubpleural macrophages with prominent
ccumulation of neutral lipid, including
holesteryl ester and triglycerides along
ith phospholipids. Multinucleated giant
ells and many foam cells containing
holesterol clefts were observed, along
ith lymphocyte accumulation. Increased
eutral lipid was also observed in hepa-
ocytes and Kupffer cells. In older chow-
ed animals, modest pleural, but no hepa-
ocyte, lipid accumulation was observed.
owever, hepatic fatty acid synthesis
athways were induced. In transgenic
ice overexpressing ABCG1, levels of
holesteryl esters in pleura and liver were
ecreased compared to wild-type con-
rols, again without a plasma lipoprotein
henotype. No atherosclerosis data were
resented.
Compared to that of the ABCA1
nockout, the ABCG1 knockout pheno-
ype is modest, with no effect on plasma
DL levels. Despite this, in vitro studies
ith peritoneal macrophages from ABCG1
nockout, ABCA1 knockout, and wild-
ype mice did show that ABCG1 was re-
ponsible for LXR-induced cholesterol
fflux to intact HDL. In contrast, as ex-87
P R E V I E Wpected, ABCA1 accounted for much of o
both LXR-inducible and baseline choles- t
terol efflux to lipid-poor apoA-I.
On the basis of these studies, we may N
now be confident that ABCG1 is respon- A
sible for much of the cholesterol efflux C
that utilizes mature HDL as an acceptor, 6
certainly in the case of macrophages. In P
addition, while similar genes may play N
some contributory role, ABCG1 is clearly
an important overall mediator of total
cholesterol efflux from macrophages in
S
some tissues, particularly under condi-
tions of cholesterol excess. Surprisingly A
thowever, despite the persuasive evi-
Mdence that it mediates cholesterol efflux
Pto HDL, ABCG1 does not appear to be C
a determinant of the plasma HDL level,
Bthe variable whose correlation with coro-
T
nary heart disease risk ultimately lay l
behind these studies. Of course, there a
are likely many determinants of athero-
B
sclerotic risk whose effect is indepen- Z
dent of plasma lipoprotein levels. How- B
(ever, whether the level of expression of
ABCG1 is one such variable remains un- F
known, and the presentation of data on G
vthis subject is eagerly awaited. Until
then, the importance for atherosclerotic K
risk both of ABCG1 and, more generally, X88wf macrophage cholesterol efflux to ma-
3ure HDL will remain open questions.
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